Cell>Point enters deal for commercialization of imaging agents

03/14/2013 | Business Wire

Cell>Point said it has secured a licensing deal with South Korean firm Hanmi Pharmaceutical. The agreement involves the development and commercialization of Cell>Point's cancer and cardiology imaging agent, to be developed through its ethylenedicysteine-glucosamine technology. The partnership will initially produce technetium-99m-labeled EC-G for SPECT and SPECT/CT uses. The collaboration will cover gallium-68-labeled EC-G for PET/CT imaging later on.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park